How does intraperitoneal LPS administration affect the composition and function of intestinal mucus?
Best insight from top research papers
Intraperitoneal administration of lipopolysaccharides (LPS) can significantly impact the composition and function of intestinal mucus. Studies have shown that exposure to LPS can lead to changes in the mucus layer thickness and goblet cell functions in the small intestine . Low doses of LPS can increase mucus layer thickness and enhance the barrier function of the intestine against luminal bacteria, while high doses of LPS can result in a decrease in mucus layer thickness, compromising the intestinal mucosal barrier and leading to chronic low-grade inflammation . Additionally, the expression of mucin-2 (MUC2), a major component of the mucus layers, is significantly increased in response to LPS exposure, especially in the uterus, suggesting a protective role of MUC2 against LPS translocation into uterine tissue .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
32 Citations | Not addressed in the paper. |
| Intraperitoneal LPS administration increases LPS levels in the intestine and uterus, decreases sIgA content, and upregulates MUC2 expression, impacting mucus barrier function and fetal immune protection. | |
29 Oct 2019 1 Citations | Intraperitoneal LPS administration alters intestinal mucus by increasing mucus layer thickness and goblet cell function at low doses, while high doses lead to mucus layer thinning and compromised function. |
| Intraperitoneal LPS administration reduces goblet cell density in the colon and alters colonic contractility, enhancing motor responses to luminal antigens like ovalbumin, potentially contributing to intestinal dysbiosis. | |
| Not addressed in the paper. |
Related Questions
What is the role of the intestinal mucus barrier in protecting against intraperitoneal LPS-induced inflammation and tissue damage?4 answersThe intestinal mucus barrier plays a crucial role in protecting against intraperitoneal LPS-induced inflammation and tissue damage. The mucus layer, primarily composed of MUC2, acts as a protective shield for intestinal epithelial cells, preventing the penetration of endotoxins like LPS. Disruption of this mucus layer can lead to damage to tight junctions, focal adhesion structures, and extracellular matrix networks, ultimately compromising the intestinal barrier function. Studies have shown that enhancing factors like HIF-1α can help maintain the integrity of the intestinal barrier, reducing inflammation and oxidative damage induced by sepsis. Additionally, compounds like naringin have been found to mitigate LPS-induced intestinal barrier damage by modulating inflammatory responses and improving antioxidant functions.
How does LPS-inflamed MSCs contribute to the development and progression of inflammatory diseases?5 answersLipopolysaccharide (LPS)-inflamed Mesenchymal Stem Cells (MSCs) play a crucial role in the development and progression of inflammatory diseases. Studies have shown that LPS exposure can induce different immune-phenotypes in MSCs. LPS stimulation affects the autophagy process in MSCs from patients with autoimmune diseases, potentially contributing to disease pathogenesis. Furthermore, LPS treatment influences the expression of TRIM65 in macrophages, impacting inflammatory responses and disease progression. Additionally, LPS-induced endotoxemia models have demonstrated that while MSCs have immunoregulatory effects, in some cases, they may not effectively attenuate inflammatory injuries, suggesting a complex interplay between MSCs and the local inflammatory environment. Overall, LPS-inflamed MSCs can modulate immune responses and contribute to the pathogenesis of inflammatory diseases through various mechanisms.
What will be the effect on bacterial LPS if the load is increased in antimicrobial peptides?5 answersIncreasing the load of antimicrobial peptides can have significant effects on bacterial lipopolysaccharide (LPS). Studies have shown that cationic antimicrobial peptides interact with LPS through electrostatic and hydrophobic interactions, potentially disrupting the LPS layer and priming it for damage. Additionally, synthetic anti-LPS peptides have been found to efficiently neutralize pathogenicity factors of Gram-negative bacteria, including LPS, and protect against sepsis. However, bacteria like Pseudomonas aeruginosa can modify their LPS to evade antimicrobial peptides, neutralizing the charge of the cell and resisting AMP killing. Furthermore, certain cationic antimicrobial peptides have shown the ability to induce changes in the aggregate structures of LPS, potentially altering their toxic activities and triggering anti-inflammatory responses.
How to generate a post-sepsis syndrome through intraperitoneal injections of LPS?5 answersIntraperitoneal injection of lipopolysaccharides (LPS) can be used to generate a post-sepsis syndrome. Different concentrations of LPS (5, 10, 15 mg/ml) were administered to male and female rats to induce sepsis and study its prognosis. The severity of sepsis can be regulated by the number of Escherichia coli cells injected into the peritoneal cavity of mice. The acute effects of the stable Ang-1 variant matrilin-1-angiopoietin-1 (MAT.Ang-1) on the microcirculation in an experimental model of sepsis were investigated. Gasdermin D (GSDMD)-mediated pyroptosis is involved in LPS-induced sepsis-associated acute kidney injury (AKI). Caspase-1 and caspase-11 may be involved in GSDMD cleavage during sepsis-associated AKI.
How does LPS administration affect the brain mice?3 answersLPS administration in mice induces neuroinflammation and affects brain function. Studies have shown that LPS injection leads to the activation of inflammation and subsequent depression-like behavior in mice. Mild neuroinflammation induced by LPS also results in region-specific microglial activation and the production of pro-inflammatory cytokines in different brain regions. Additionally, LPS exposure has been found to impair the glymphatic system, which is responsible for waste clearance in the brain, leading to decreased perivascular distribution of cerebrospinal fluid (CSF). Prenatal exposure to LPS has also been shown to have long-lasting effects on offspring, including increased inflammation, altered cortical cytoarchitecture, and behavioral impairments. Overall, LPS administration in mice has been found to have significant effects on neuroinflammation, microglial activation, glymphatic function, and brain development and behavior.
What concentration of LPS can kill macrophages?4 answersThe concentration of LPS required to kill macrophages depends on various factors. In one study, it was found that more than 10 ng/mL of LPS was necessary in combination with 300 ng/mL of triptolide to induce cytotoxicity in macrophages. Another study showed that concentrations of LPS as low as 1 ng/mL suppressed the activity of the scavenger receptor on macrophages. Additionally, macrophages activated with LPS for 8 hours showed cytotoxicity against tumor cells, but this cytotoxic capacity was lost if the macrophages were maintained in medium for an additional 16 hours. Therefore, the concentration of LPS required to kill macrophages can vary depending on the specific experimental conditions and the presence of other factors such as triptolide or tumor cells.